Competition for additional information regarding our competitors. This competition and competition with approved therapies will reduce the number and types of patients available for clinical trials involving our product candidates, because some patients who might have opted to enroll in our trials may instead opt to pursue a treatment regimen using an approved therapy or enroll in a trial conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we c...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071563 | EDGAR | 97K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027736 | EDGAR | — |
| 2024-02-26 | 2023-12-31 | 0000950170-24-020145 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0000950170-23-004645 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002297 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001564590-21-010276 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001564590-20-014169 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266923 | EDGAR | 69K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104022 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065660 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122303 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092783 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055655 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059391 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039805 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018805 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022590 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016059 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008496 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-25 | 0001193125-26-071517 | EDGAR | 3K words |
| 2025-11-05 | 0001193125-25-266836 | EDGAR | — |
| 2025-10-17 | 0001193125-25-241736 | EDGAR | — |
| 2025-09-10 | 0001193125-25-200078 | EDGAR | — |
| 2025-08-06 | 0000950170-25-103983 | EDGAR | — |
| 2025-06-27 | 0001193125-25-151254 | EDGAR | — |
| 2025-06-24 | 0001193125-25-145242 | EDGAR | — |
| 2025-06-18 | 0001193125-25-142735 | EDGAR | — |
| 2025-05-07 | 0000950170-25-065618 | EDGAR | — |
| 2025-02-26 | 0000950170-25-027707 | EDGAR | — |
108 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001628171 |
| Ticker | RVMD |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.revmed.com |
| Listed | 2020-02-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report